Document is current
Any future updates will be listed below
-
Authors
Guedes, Mariana
Gathara, David
López-Hernández, Inmaculada
Pérez-Crespo, Pedro María Martínez
Pérez-Rodríguez, María Teresa
Sousa, Adrian
Plata, Antonio
Reguera-Iglesias, Jose María
Boix-Palop, Lucía
Dietl, Beatriz
Blanco, Juan Sevilla
Castillo, Carlos Armiñanzas
Galán-Sánchez, Fátima
Kindelán, Clara Natera
Jover-Saenz, Alfredo
Aguirre, Josune Goikoetxea
Alemán, Ana Alemán
Ciordia, Teresa Marrodán
del Arco Jiménez, Alfonso
Fernandez-Suarez, Jonathan
Lopez-Cortes, Luis Eduardo
Rodríguez-Baño, Jesús
,
Leon, Eva
Camacho, Inés Pérez
García, David Vinuesa
Pedragosa, Jordi Cuquet
Molina, Isabel María Reche
Bahamonde-Carrasco, Alberto
Rodríguez, Carmen Herrero
García, Marcos Guzmán
Sánchez-Porto, Antonio
Amat, Alejandro Smithson
de Lucas, Esperanza Merino
Quintero, Jesús Canueto
- License Information
-
More Information
Article History
Received: 3 March 2024
Accepted: 27 April 2024
First Online: 6 May 2024
Declarations
:
: This study was conducted according with the Declaration of Helsinki and national and institutional standards. PRO-BAC study was approved by the Spanish Medicines Agency and the Ethics Committee of the Hospital Universitario Virgen Macarena with waiver for informed consent (approval reference code: FIS-AMO-201601). Approval was also obtained at each participating centre. This secondary data analysis study was approved by London School of Hygiene and Tropical Medicine research Ethics Committee (approval reference code: 28651).
: Not applicable.
: LELC has been scientific advisor for Angelini, speaker for Angelini, ViiV, Gilead and Correvio, and has served as trainer for ViiV. JRB. has received honoraria from Merck for accredited educational activities. The other authors report no conflicts of interest relevant to this article.
